CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-05-16): Roche gets FDA approval for Pegasys in hepatitis B

Regulatory

Roche gets FDA approval for Pegasys in hepatitis B

Last Updated: 2005-05-16 15:45:36 -0400 (Reuters Health)

SAN FRANCISCO (Reuters) - Swiss drugmaker Roche Holding AG said on Friday the U.S. Food and Drug Administration approved its Pegasys hepatitis drug to be used in patients with the chronic form of hepatitis B.

Roche said the drug was approved for both HBeAg-positive and HBeAg-negative disease.

Chronic hepatitis B disease causes more than 5,000 deaths a year in the United States, Roche said. The Centers for Disease Control estimates that 1.25 million people in the United States are chronically infected with the disease.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.